GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » InnovAge Holding Corp (NAS:INNV) » Definitions » EV-to-EBITDA

INNV (InnovAge Holding) EV-to-EBITDA : 77.60 (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is InnovAge Holding EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, InnovAge Holding's enterprise value is $644.7 Mil. InnovAge Holding's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was $8.3 Mil. Therefore, InnovAge Holding's EV-to-EBITDA for today is 77.60.

The historical rank and industry rank for InnovAge Holding's EV-to-EBITDA or its related term are showing as below:

INNV' s EV-to-EBITDA Range Over the Past 10 Years
Min: -480.91   Med: -22.44   Max: 830.32
Current: 77.6

During the past 6 years, the highest EV-to-EBITDA of InnovAge Holding was 830.32. The lowest was -480.91. And the median was -22.44.

INNV's EV-to-EBITDA is ranked worse than
93.18% of 484 companies
in the Healthcare Providers & Services industry
Industry Median: 12.425 vs INNV: 77.60

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-15), InnovAge Holding's stock price is $4.44. InnovAge Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.130. Therefore, InnovAge Holding's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


InnovAge Holding EV-to-EBITDA Historical Data

The historical data trend for InnovAge Holding's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnovAge Holding EV-to-EBITDA Chart

InnovAge Holding Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBITDA
Get a 7-Day Free Trial - -474.26 55.94 -28.69 620.40

InnovAge Holding Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.26 -54.78 -55.07 620.40 104.40

Competitive Comparison of InnovAge Holding's EV-to-EBITDA

For the Medical Care Facilities subindustry, InnovAge Holding's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnovAge Holding's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, InnovAge Holding's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where InnovAge Holding's EV-to-EBITDA falls into.



InnovAge Holding EV-to-EBITDA Calculation

InnovAge Holding's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=644.660/8.307
=77.60

InnovAge Holding's current Enterprise Value is $644.7 Mil.
InnovAge Holding's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnovAge Holding  (NAS:INNV) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

InnovAge Holding's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=4.44/-0.130
=At Loss

InnovAge Holding's share price for today is $4.44.
InnovAge Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.130.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


InnovAge Holding EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of InnovAge Holding's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


InnovAge Holding Business Description

Traded in Other Exchanges
N/A
Address
8950 East Lowry Boulevard, Denver, CO, USA, 80230
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
Executives
Nicole Damato officer: CHIEF LEGAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Teresa Sparks director 40 BURTON HILLS BOULEVARD SUITE 500, NASHVILLE TN 37215
Benjamin C Adams officer: CHIEF FINANCIAL OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patricia Fontneau director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Christine Bent officer: CHIEF OPERATIONS OFFICER 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Thomas Scully director 320 PARK AVENUE, SUITE # 2500, NEW YORK NM 10022
Richard Feifer officer: CHIEF MEDICAL OFFICER C/O GENESIS HEALTHCARE, INC., 101 EAST STATE STREET, KENNETT SQUARE PA 19348
James G Carlson director 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Patrick T Blair officer: PRESIDENT 8950 E. LOWRY BOULEVARD, DENVER CO 80230
Caroline Dechert director 580 CALIFORNIA ST., SUITE 1700, SAN FRANCISCO CA 94104
Pavithra Mahesh director 601 LEXINGTON AVE., 53RD FLOOR, NEW YORK NY 10022
Maureen Hewitt director, officer: CEO, President and Director 8950 E. LOWRY BLVD., DENVER CO 80230
Maria Lozzano officer: CORPORATE COO 8950 E. LOWRY BLVD., DENVER CO 80230
Robin Doerr officer: CHIEF SALES AND MKTG. OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230
Melissa Welch officer: CHIEF MEDICAL OFFICER 8950 E. LOWRY BLVD., DENVER CO 80230